- Home
- DTST vs NRSN Comparison
DTST vs NRSN Comparison
Compare DTST & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTST | NRSN |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | Israel |
| Employees | 55 | 15 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 28.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DTST | NRSN |
|---|---|---|
| Price | $4.05 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 9.6K | ★ 145.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $0.68 |
| 52 Week High | $5.44 | $2.60 |
Technical Indicators
Market Signals| Indicator | DTST | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 46.63 |
| Support Level | $3.74 | $0.85 |
| Resistance Level | $4.37 | $1.30 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 32.26 | 28.57 |
Price Performance
Historical ComparisonAbout DTST Data Storage Corporation
Data Storage Corporation engages in providing cybersecurity, compliance and cloud computing solutions. The company's segment includes Nexxis Inc; CloudFirst Europe Ltd and CloudFirst Technologies Corporation and Corporate. It generates maximum revenue from the CloudFirst Technologies Corporation segment. The company's solutions include infrastructure, disaster recovery, email archival, compliance, electronic vaulting, virtualized recovery, telecom recovery services, and continuous data protection.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.